Abstract Details

Title Spine atrophy and sensory-motor disability in African Americans with Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-051

Objective To investigate the extent of spinal cord (SC) atrophy in African Americans (AA) with multiple sclerosis (MS) compared to age-, sex- and race matched healthy controls (HC).

Background

AA with MS present a more severe disease course than Caucasians with MS, but the contribution of SC lesions and cervical SC (CSC) damage to clinical disability has never been explored.

Design/Methods Twenty-nine AA patients (23F, mean age 38.85 ± 11.78 yrs, disease duration 4.08 ± 3.51 yrs, median EDSS 2.0, range [0-6.5]) and 21 AA HC (15F, mean age 33.52 ± 10.15 yrs) were prospectively enrolled as part of an ongoing longitudinal study. In all subjects, an extensive sensory-motor evaluation was performed including: 9-hole peg test (9-HPT), grooved pegboard test (GPT), 25-foot walk test (25-FWT), 2-minutes walk test (2-MWT), evaluation of upper and lower limbs strength, grip strength, vibration sensitivity and balance. Normalized CSC volume (nCSCV) was computed using the SCToolbox. Between-group comparison was performed with ANCOVA adjusted for age and gender. Partial correlations were also adjusted for disease duration.

Results A total number of 33 CSC lesions were found in AA patients (median: 1, range: [0-5]). Sixty-nine percent of the lesions were limited in extension to one cervical level with the highest lesion frequency at C2 (22%). AA showed lower nCSCV than HC (AA: 64.24 ± 5.64 mm³, HC: 68.41± 4.21 mm³, p=0.019). Lesion count was correlated with hand vibration sensitivity (r=0.78, p=0.003), while nCSCV was correlated with 2-MWT (r=0.47, p=0.021), grip strength (r=0.49, p=0.016) and lower limbs strength quantified as ankle plantar and dorsiflexion (r=0.61, p=0.013; r=0.50, p=0.047) and showed association trends with upper limb strength quantified as elbow flexion (r=0.38, p=0.070), foot vibration sensitivity (r=-0.50, p=0.080) and balance test (r=-0.43, p=0.080).

Conclusions

CSC damage in terms of both macroscopic lesions and atrophy significantly impacts motor and sensory performances in AA with MS.

Authors/Disclosures
PRESENTER	No disclosure on file
Maria Petracca, PhD (University of Rome Sapienza)	Dr. Petracca has nothing to disclose.
	No disclosure on file
Giacomo Boffa (Department of Neuroscience, University of Genova)	Mr. Boffa has nothing to disclose.
	No disclosure on file
Christopher Langston, MD (Montefiore Nyack Hospital)	No disclosure on file
Daniel P. Kurz, MD (University of Chicago)	An immediate family member of Dr. Kurz has received personal compensation for serving as an employee of Grainger. Dr. Kurz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Foundation for Sarcoidosis Research. An immediate family member of Dr. Kurz has or had stock in Grainger. The institution of Dr. Kurz has received research support from Biogen.
Ilena George, MD	The institution of Dr. George has received research support from Biogen.
Claire Riley, MD, FAAN	Dr. Riley has received personal compensation for serving as an employee of AstraZeneca. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cabaletta Bio. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics.
Jonathan Howard, MD (NYU Langone Health)	Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MCE Conferences. Dr. Howard has received publishing royalties from a publication relating to health care. Dr. Howard has received publishing royalties from a publication relating to health care. Dr. Howard has received publishing royalties from a publication relating to health care. Dr. Howard has a non-compensated relationship as a Test writer with ABPN that is relevant to AAN interests or activities.
Sylvia Klineova, MD (Icahn School of Medicine At Mount Sinai)	Dr. Klineova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Klineova has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Klineova has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Klineova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion.
Matilde Inglese, MD, PhD (University of Genoa)	Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI GENZYME. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK-SERONO. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MS Journal.

��ɫ��

��ɫ��